Please select an option
Please enter a valid email address
Please complete this field
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fund is dedicated to investing in intellectual property commercialisation.
We make UCL’s research physical and life sciences ideas happen.
Discover companies, licensing projects and proof-of-concepts backed by the Fund across Life Sciences and Physical Sciences. (Here listed only the publicly announced investments)
Biotech company advancing a broad pipeline of potentially transformative therapeutic programs
Preclinical company developing small-molecule modulators of key targets in sleep and Alzheimer's disease
Developing small molecule stabilisers to stabilise transthyretin in a rare, progressive disease called ATTR
Acquired company that created natural language processing technology to help machines answer questions.
Biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases
Fuel cell company on a mission to help the world achieve net zero
Climate tech company using AI solutions to decarbonise cement and steel
Allogeneic stem cell derived therapy for the treatment of glaucoma
Medtech company developing, manufacturing and commercialising cardiovascular devices
Commercialising a portfolio of world-leading gene therapies to treat focal refractory epilepsy
Biotech company developing immunoglobulin E (IgE) antibodies to treat cancer
Spur Therapeutics (formerly Freeline Therapeutics) is a clinical-stage biotechnology company focused on developing life-changing gene therapies for debilitating chronic conditions.
Company inventing and developing fast-charging batteries
Cell therapy for peripheral nerve repair
Clinical stage program targeting hard-to-treat solid tumours with a novel G-quadruplex targeting small molecule drug
AI company aiming to help developers and data scientists share information securely
Gene therapy targeting novel circuity for degenerative retinal diseases.
AI company creating tools allowing businesses to integrate natural language processing (NLP)
Developing an all-silicon non-volatile memory
Augmented worker platform focused on improving quality and efficiency in production lines
Clinical-stage gene therapy company developing treatments for ocular diseases, NASDAQ: MGTX
Clinical-stage company developing a platform for biologics autoregulation to expand therapeutic window in oncology, haematology and autoimmune disease
Company using AI to improve endoscopic procedures for better early detection and diagnosis of cancer
Engineered gamma delta (γδ) T cell platform for solid tumours.
Ex vivo lentiviral gene therapy company providing curative treatment for devastating inherited diseases, NASDAQ: ORTX
UCL spinout using light to train and run large machine learning models orders of magnitude faster with only a fraction of power
Real time graph engine at scale
Quantum computing company developing novel techniques to deliver real-world applications
Targeting LRG1 as a pathological regulator in a range of vascular diseases
AI startup leveraging active inference and the free energy principle to build ‘Agentic AI’ for the real world.
Developing cell therapy treatments for organ transplant patients and people with auto-immune conditions
EdTech platform connecting online maths tutors with pupils
Latest news and views from the team, companies and the UCL ecosystem.
UCLTF offers investment throughout the commercialisation journey. We fund proof-of-concept and development projects, and support founding teams with company formation.
